BIOMAT Database Logo BIOMAT Database Logo

Drug reaction with eosinophilia and systemic symptoms induced by carbamazepine: DRESSed to kill. 2011

Drieske A Halink, and Radboud M Marijnissen, and Annemarieke A Schut, and Richard C Oude Voshaar
Pro Persona, Department of Old Age Psychiatry, Arnhem, the Netherlands.

Two elderly patients with dementia-related behavioral problems developed rash, edema, eosinophilia and systemic symptoms after administration of carbamazepine. Drug reaction with eosinophilia and systemic symptoms (DRESS) was diagnosed with some delay. The relevance and complexity of recognizing DRESS are shown. Symptoms occur 1 to 8 weeks after start of carbamazepine, progress slowly and are similar to those in infections and neoplastic disorders. DRESS is a severe and potentially fatal complication, occurring in 1 of every 1000 to 10,000 patients using antiepileptic drugs. Treatment consists of immediate withdrawal of the offending drug, while reexposure should be avoided. First-degree relatives need to be informed about being at increased risk.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002220 Carbamazepine A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties. Amizepine,Carbamazepine Acetate,Carbamazepine Anhydrous,Carbamazepine Dihydrate,Carbamazepine Hydrochloride,Carbamazepine L-Tartrate (4:1),Carbamazepine Phosphate,Carbamazepine Sulfate (2:1),Carbazepin,Epitol,Finlepsin,Neurotol,Tegretol
D003875 Drug Eruptions Adverse cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions. Dermatitis Medicamentosa,Dermatitis, Adverse Drug Reaction,Maculopapular Drug Eruption,Maculopapular Exanthem,Morbilliform Drug Reaction,Morbilliform Exanthem,Drug Eruption,Drug Eruption, Maculopapular,Drug Eruptions, Maculopapular,Drug Reaction, Morbilliform,Drug Reactions, Morbilliform,Eruption, Drug,Eruption, Maculopapular Drug,Eruptions, Drug,Eruptions, Maculopapular Drug,Exanthem, Maculopapular,Exanthem, Morbilliform,Exanthems, Maculopapular,Exanthems, Morbilliform,Maculopapular Drug Eruptions,Maculopapular Exanthems,Morbilliform Drug Reactions,Morbilliform Exanthems,Reaction, Morbilliform Drug,Reactions, Morbilliform Drug
D004802 Eosinophilia Abnormal increase of EOSINOPHILS in the blood, tissues or organs. Eosinophilia, Tropical,Hypereosinophilia,Tropical Eosinophilia,Hypereosinophilias,Tropical Eosinophilias
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000927 Anticonvulsants Drugs used to prevent SEIZURES or reduce their severity. Anticonvulsant,Anticonvulsant Drug,Anticonvulsive Agent,Anticonvulsive Drug,Antiepileptic,Antiepileptic Agent,Antiepileptic Agents,Antiepileptic Drug,Anticonvulsant Drugs,Anticonvulsive Agents,Anticonvulsive Drugs,Antiepileptic Drugs,Antiepileptics,Agent, Anticonvulsive,Agent, Antiepileptic,Agents, Anticonvulsive,Agents, Antiepileptic,Drug, Anticonvulsant,Drug, Anticonvulsive,Drug, Antiepileptic,Drugs, Anticonvulsant,Drugs, Anticonvulsive,Drugs, Antiepileptic
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Drieske A Halink, and Radboud M Marijnissen, and Annemarieke A Schut, and Richard C Oude Voshaar
Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms syndrome induced by cilostazol and carbamazepine.
August 2012, The Journal of dermatology,
Drieske A Halink, and Radboud M Marijnissen, and Annemarieke A Schut, and Richard C Oude Voshaar
Carbamazepine-associated Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome.
January 2021, Journal of pediatric neurosciences,
Drieske A Halink, and Radboud M Marijnissen, and Annemarieke A Schut, and Richard C Oude Voshaar
Aplastic anaemia following carbamazepine-induced drug reaction with eosinophilia and systemic symptoms syndrome.
November 2019, Internal medicine journal,
Drieske A Halink, and Radboud M Marijnissen, and Annemarieke A Schut, and Richard C Oude Voshaar
[Drug reaction with eosinophilia and systemic symptoms due to carbamazepine. Pediatric case].
June 2018, Archivos argentinos de pediatria,
Drieske A Halink, and Radboud M Marijnissen, and Annemarieke A Schut, and Richard C Oude Voshaar
Pustular-type drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms due to carbamazepine with systemic muscle involvement.
February 2013, The Journal of dermatology,
Drieske A Halink, and Radboud M Marijnissen, and Annemarieke A Schut, and Richard C Oude Voshaar
[Drug rash with eosinophilia and systemic symptoms syndrome induced by carbamazepine: Case report].
June 2017, Biomedica : revista del Instituto Nacional de Salud,
Drieske A Halink, and Radboud M Marijnissen, and Annemarieke A Schut, and Richard C Oude Voshaar
Rivaroxaban-Induced Drug Reaction With Eosinophilia and Systemic Symptoms.
January 2016, Journal of investigational allergology & clinical immunology,
Drieske A Halink, and Radboud M Marijnissen, and Annemarieke A Schut, and Richard C Oude Voshaar
Statin-induced drug reaction with eosinophilia and systemic symptoms.
February 2022, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology,
Drieske A Halink, and Radboud M Marijnissen, and Annemarieke A Schut, and Richard C Oude Voshaar
Ganciclovir-induced drug reaction with eosinophilia and systemic symptoms.
October 2023, Skin health and disease,
Drieske A Halink, and Radboud M Marijnissen, and Annemarieke A Schut, and Richard C Oude Voshaar
Valacyclovir-induced drug reaction with eosinophilia and systemic symptoms
July 2022, European journal of dermatology : EJD,
Copied contents to your clipboard!